|
KR20200047466A
|
|
Novel Pharmaceutical Formulation with Improved Stability Comprising Amorphous Empagliflozin
|
|
KR20200038895A
|
|
Novel Pharmaceutical Formulation with Improved Stability Comprising Taxanes, Pharmaceutically Acceptable Salt or Hydrates Thereof
|
|
KR20200020746A
|
|
Hybrid compounds and preparation method for the same
|
|
WO2020141825A1
|
|
Tablet and method of preparing same
|
|
KR20200133528A
|
|
Pyrimido-pyrimidin derivatives and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases
|
|
KR20200129705A
|
|
PI3K Inhibitor of Amorphous and Pharmaceutical Composition Comprising the same
|
|
KR20200129704A
|
|
Crystal Polymorphism of PI3K Inhibitor and Method for Producing the Same
|
|
KR20200115934A
|
|
Pyrrolidine derivatives as inhibitor of fibroblast activation protein (fap) and pharmaceutical composition including the same
|
|
KR20200055117A
|
|
Pharmaceutical composition for prevention or treatment of cancer, including PI3 kinase inhibitor and cytotoxic anticancer agent
|
|
KR20200082702A
|
|
Method for manufacturing lafutidine crystal with high purity
|
|
WO2019112381A1
|
|
Composition comprising pi3 kinase inhibitor and bcl-2 inhibitor
|
|
KR20200058865A
|
|
Bilyaer tablets and method of preparing bilyaer tablet
|
|
KR20200012637A
|
|
Pharmaceutical formulation comprising edoxaban and preparation method thereof
|
|
KR20200007332A
|
|
Pyrimininone derivative compounds and use thereof
|
|
KR101992400B1
|
|
Pharmaceutical formulation
|
|
KR101926853B1
|
|
Pharmaceutical composition
|
|
KR101974412B1
|
|
Pharmaceutical formulation and preparation method thereof
|
|
KR101997652B1
|
|
Pharmaceutical formulation
|
|
KR20190064208A
|
|
Solid dispersion comprising Fimasartan
|
|
KR20190064210A
|
|
Phamaceutical composition comprising Fimasartan
|
